专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11598780B2 Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor 有权
公开(公告)号：US11598780B2
公开(公告)日：2023-03-07
申请号：US16753684
申请日：2018-10-05
申请人： The University of Chicago , OncoTherapy Science, Inc.
发明人： Yusuke Nakamura , Jae-Hyun Park , Sachiko Yoshimura , Tetsuro Hikichi
IPC分类号： G01N33/68 , A61K35/17 , C07K14/725 , C12N5/0783 , C12N15/85 , G01N33/50 , G01N33/569
摘要： Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.

2. 发明申请

US20200341001A1 SCREENING OF T LYMPHOCYTES FOR CANCER-SPECIFIC ANTIGENS 审中-公开
公开(公告)号：US20200341001A1
公开(公告)日：2020-10-29
申请号：US16753684
申请日：2018-10-05
申请人： The University of Chicago , OncoTherapy Science, Inc.
发明人： Yusuke Nakamura , Jae-Hyun Park , Sachiko Yoshimura , Tetsuro Hikichi
IPC分类号： G01N33/68 , G01N33/569 , G01N33/50 , C12N15/85 , C12N5/0783 , C07K14/725 , A61K35/17
摘要： Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.

3. 发明授权

US11266729B2 UBE2T peptides and vaccines containing the same 有权
公开(公告)号：US11266729B2
公开(公告)日：2022-03-08
申请号：US16120102
申请日：2018-08-31
申请人： OncoTherapy Science, Inc.
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K39/00 , C12N5/0783 , C12N5/078 , C07K16/40 , A61K31/7088 , C12N9/00 , G01N33/574
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

4. 发明授权

US10092634B2 UBE2T peptides and vaccines containing the same 有权
公开(公告)号：US10092634B2
公开(公告)日：2018-10-09
申请号：US14400169
申请日：2013-09-09
申请人： OncoTherapy Science, Inc.
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K39/00 , A61K31/7088 , C12N9/00 , C07K16/40 , G01N33/574
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

5. 发明授权

US09597382B2 KNTC2 peptides and vaccines containing the same 有权
公开(公告)号：US09597382B2
公开(公告)日：2017-03-21
申请号：US14772003
申请日：2014-03-11
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： C07K14/00 , A61K39/00 , C07K14/47 , G01N33/50 , C07K7/06 , C07K16/18 , G01N33/574 , A61K38/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/5154 , C07K7/06 , C07K14/47 , C07K16/18 , G01N33/505 , G01N33/57484
摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, provided such modified versions retain the requisite CTL inducibility of the original sequences.

6. 发明申请

US20140255437A1 TOPK PEPTIDES AND VACCINES INCLUDING THE SAME 有权
标题翻译： TOPK PEPTIDES和疫苗，包括它们
公开(公告)号：US20140255437A1
公开(公告)日：2014-09-11
申请号：US14353261
申请日：2012-10-25
申请人： c/o ONCOTHERAPY SCIENCE, INC.
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
IPC分类号： A61K39/00 , C07K16/18 , C07K7/06
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/0005 , A61K2039/5154 , A61K2039/572 , C07K7/06 , C07K14/4748 , C07K16/18 , C07K16/40 , C07K2317/34 , C12N9/12 , C12N9/1205 , C12Y207/12002 , G01N33/505 , G01N33/574
摘要： The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.
摘要翻译：本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

7. 发明申请

US20150315239A1 METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES 审中-公开
标题翻译：通过管理WDRPUH EPITOPE肽诱导免疫应答的方法
公开(公告)号：US20150315239A1
公开(公告)日：2015-11-05
申请号：US14805424
申请日：2015-07-21
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： C07K7/06 , A61K39/00
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1764 , A61K39/0011 , C07K14/47 , C07K14/4748 , C12N5/0638 , C12N5/0639
摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
摘要翻译：本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。本发明的肽也可以用作疫苗。

8. 发明授权

US10711047B2 CDCA1 epitope peptides and vaccines containing the same 有权
公开(公告)号：US10711047B2
公开(公告)日：2020-07-14
申请号：US15176444
申请日：2016-06-08
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K39/00 , C07K14/47 , C12N5/0783 , C07K7/06 , A61K38/00
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

9. 发明授权

US09745343B2 Method of inducing an immune response by administering WDRPUH epitope peptides 有权
公开(公告)号：US09745343B2
公开(公告)日：2017-08-29
申请号：US14805424
申请日：2015-07-21
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K38/04 , A61K38/08 , C07K7/06 , A61K39/00 , C07K14/47 , A61K38/17 , C12N5/0783 , C12N5/0784 , A61K38/00
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1764 , A61K39/0011 , C07K14/47 , C07K14/4748 , C12N5/0638 , C12N5/0639
摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

10. 发明授权

US09446106B2 NEIL3 peptides and vaccines including the same 有权
公开(公告)号：US09446106B2
公开(公告)日：2016-09-20
申请号：US14689302
申请日：2015-04-17
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura , Yoichi Furukawa
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , A61K39/39 , C12N9/88
CPC分类号： C07K14/4748 , A61K39/00 , A61K39/0011 , A61K39/39 , A61K2039/53 , A61K2039/572 , C12N9/88 , C12Y402/99018 , Y02A50/396
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式